

# Advances in Multiple Sclerosis (MS)

Median life expectancy **~17 years** after MS disease onset<sup>1</sup>

**1948**

**No standardized method** for assessing the progression of MS

**1960**

Average time between a person's first symptom and a definitive diagnosis of MS - **7 years**<sup>2</sup>

**1970**

The **Expanded Disability Status Scale\*** was developed to assess disability in MS<sup>3,4</sup>

**1983**  
**1984**

Only **~20%** of people with MS were employed<sup>5</sup>

**1983**  
**1984**

Treatments available for MS could only target **disease symptoms**<sup>6</sup>

**1990**

First **disease modifying therapy (DMT)** approved for people with relapsing forms of MS (RMS)<sup>6</sup>

**1993**

**MRI** measurements integrated into best practice for diagnosing MS<sup>7</sup>

**2001**

**6 DMTs available** for people with RMS, all required injection<sup>8</sup>

**2008**

First **oral DMT** approved for people with RMS<sup>9\*\*</sup>

**2010**

MS is mentioned every **13 seconds** in the **online space**<sup>10</sup>

**Now**

**3 oral DMTs available** for people with RMS<sup>8\*\*\*</sup>

**Now**

Average time between a person's first symptom and a definitive diagnosis of MS - **6 months**, thanks to advancements in technology<sup>2</sup>

**Now**

**Brain shrinkage** (brain volume loss) is a predictor of long-term disability in RMS, as measured by MRI<sup>11</sup>

**Now**

RMS treatment goals are centered around achieving **no evidence of disease activity (NEDA)** in 4 key measures of disease: relapses, MRI lesions, brain shrinkage (brain volume loss) and disability progression

**Now**

**~50%** of people with MS will still be employed 10 years after diagnosis<sup>12</sup>

**Now**

Median life expectancy for people with MS is only **13% shorter** than the general population<sup>13,14</sup>

**Now**

## References

1. Ipsen J Jr. Life expectancy and probable disability multiple sclerosis. N Engl J Med. 1950 Dec 7;243(23):909-13.
2. Rolak, A. MS: The Basic Facts Clin Med Res. 2003 Jan; 1(1): 61-62.
3. Kornblith AB et al. Employment in individuals with multiple sclerosis. Int J Rehabil Res. 1986;9(2):155-65.
4. [http://www.nationalmssociety.org/For-Professionals/Researchers/Resources-for-Researchers/Clinical-Study-Measures/Functional-Systems-Scores-\(FSS\)-and-Expanded-Disab](http://www.nationalmssociety.org/For-Professionals/Researchers/Resources-for-Researchers/Clinical-Study-Measures/Functional-Systems-Scores-(FSS)-and-Expanded-Disab). Accessed March 2015.
5. LaRocca N, Katz R, Kendall P, Scheinberg L. The role of disease and demographic factors in the mortality of patients with multiple sclerosis. Arch Neurol. 1982 Apr;39(4):256.
6. Formulary Journal: Disease-modifying therapies for multiple sclerosis: Focus on future direction. <http://formularyjournal.modernmedicine.com/formularyjournal/news/clinical/clinical-pharmacology/disease-modifying-therapies-multiple-sclerosis#sthash.5umJ6YU.dpuf>. Accessed March 2015.
7. Eikelboom, M.J. Biological markers in multiple sclerosis related to disease activity and progression. 2007.
8. <http://www.nationalmssociety.org/Treating-MS/Medications>. Accessed March 2015.
9. <http://www.webmd.com/multiple-sclerosis/news/20100922/gilenya-first-oral-ms-drug-gets-fda-nod> Accessed March 2015.
10. Data on file. Novartis Pharma AG.
11. Popescu V et al.; on behalf of the MAGNIMS Study Group. Brain atrophy and lesion load predict long term disability in multiple sclerosis. J Neurol Neurosurg Psychiatry. 2013 Mar 23.
12. Pfeleger et al. Social consequences of multiple sclerosis (1): early pension and temporary unemployment—a historical prospective cohort study. Mult Scler. 2010 Jan;16(1):121-6.
13. Torkildsen et al. Survival and cause of death in multiple sclerosis: results from a 50-year follow-up in Western Norway. Mult Scler. 2008 Nov;14(9):1191-8.
14. [http://www.thi.no/eway/default.aspx?pid=240&trg=List\\_6673&Main\\_6664=6898:0:25:7524:1:0:0:0:0&MainContent\\_6898=6671:0:25:7525:1:0:0:0:0&List\\_6673=6674:0:25:7528](http://www.thi.no/eway/default.aspx?pid=240&trg=List_6673&Main_6664=6898:0:25:7524:1:0:0:0:0&MainContent_6898=6671:0:25:7525:1:0:0:0:0&List_6673=6674:0:25:7528) Accessed March 2015.

\* The Expanded Disability Status Scale (EDSS) is a method of quantifying disability in multiple sclerosis and monitoring changes in the level of disability over time  
 \*\* By the Federal Service on Surveillance in Healthcare and Social Development, the Russian health authority  
 \*\*\* In the US